GGrantIndex
← Leaderboards

David Eric Gerber

Ut Southwestern Medical Center

$9,524,578
Attributed
$12,051,370
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY201525
$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,051,370 · 7

By mechanism

UG1$5,429,669 · 1
U01$3,100,249 · 1
U10$2,040,908 · 1
K24$736,678 · 1
R01$528,157 · 1
R03$161,709 · 1

Top collaborators

Most similar at Ut Southwestern Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsRecording Of Previous EventsBaseClinical ResearchMalignant Neoplasm Of LungResearch PersonnelMalignant NeoplasmsMentorsBioinformaticsLeadershipGrantProgramsCareer DevelopmentBasic ScienceFundingPositioning AttributeLeadClinicAreaCancer CenterEligibility DeterminationEnrollmentInnovationAdult

Grant awards (29)

UT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Funded Extension Supplement YR6$697,907
UG1 · FY2025 · CA · contact PI
TCR-antigen foundation model to empower TCR-based diagnostics and therapeutics$528,157
R01 · FY2025 · AI
UT Southwestern Simmons Comprehensive Cancer Center Clinical Oncology Research Career Development Award$54,000
K12 · FY2025 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site$747,907
UG1 · FY2024 · CA · contact PI
Finding the optimal balance of immunotherapy efficacy and toxicity.$543,590
U01 · FY2024 · AI · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site$779,640
UG1 · FY2023 · CA · contact PI
Finding the optimal balance of immunotherapy efficacy and toxicity.$568,167
U01 · FY2023 · AI · contact PI
UT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4$45,278
UG1 · FY2023 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site$734,640
UG1 · FY2022 · CA · contact PI
Finding the optimal balance of immunotherapy efficacy and toxicity.$574,731
U01 · FY2022 · AI · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site$835,017
UG1 · FY2021 · CA · contact PI
Finding the optimal balance of immunotherapy efficacy and toxicity.$583,185
U01 · FY2021 · AI · contact PI
Finding the optimal balance of immunotherapy efficacy and toxicity.$201,354
U01 · FY2021 · AI · contact PI
Finding the optimal balance of immunotherapy efficacy and toxicity.$40,189
U01 · FY2021 · AI · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site$734,640
UG1 · FY2020 · CA · contact PI
Finding the optimal balance of immunotherapy efficacy and toxicity.$589,033
U01 · FY2020 · AI · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site$120,000
UG1 · FY2020 · CA · contact PI
Development of New Cancer Treatments and Investigators$117,031
K24 · FY2020 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site$734,640
UG1 · FY2019 · CA · contact PI
Development of New Cancer Treatments and Investigators$117,031
K24 · FY2019 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10$644,932
U10 · FY2018 · CA · contact PI
Development of New Cancer Treatments and Investigators$168,058
K24 · FY2018 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10$700,000
U10 · FY2017 · CA · contact PI
Development of New Cancer Treatments and Investigators$167,279
K24 · FY2017 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10$50,000
U10 · FY2017 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10$645,976
U10 · FY2016 · CA · contact PI
Development of New Cancer Treatments and Investigators$167,279
K24 · FY2016 · CA · contact PI
Evaluating prior cancer exclusion policy to increase lung cancer trial accrual$80,959
R03 · FY2016 · CA · contact PI
Evaluating prior cancer exclusion policy to increase lung cancer trial accrual$80,750
R03 · FY2015 · CA · contact PI